Regencell Bioscience Holdings Limited (Nasdaq: RGC) is down sharply after disclosing an at-the-market (ATM) equity offering program that allows the company to sell up to $500,000,000 of ordinary shares from time to time. The company entered into a sales agreement with Univest Securities, LLC as sales agent, and noted shares may be sold on Nasdaq at prevailing market prices, through market makers, or via other permitted methods, creating an immediate dilution and supply-overhang concern for existing shareholders. (stocktitan.net)

The program is tied to an automatically effective shelf registration statement on Form F-3 and a prospectus supplement filed March 30, 2026. Regencell emphasized it is not obligated to sell any shares under the ATM, and that timing/amount of any sales will depend on factors determined by the company—language that often increases uncertainty for near-term price action because traders cannot easily handicap when issuance may hit the tape. (stocktitan.net)

Regencell said it currently intends to use any net proceeds primarily for working capital, capital expenditures and general corporate purposes. That broad use-of-proceeds framing signals flexibility, but also provides limited visibility into specific milestones tied to the potential fundraising—another factor that can weigh on sentiment in the immediate aftermath of an ATM announcement. (stocktitan.net)